Inspire Medical Systems, Inc. (NYSE:INSP) Receives $271.29 Average PT from Brokerages

Shares of Inspire Medical Systems, Inc. (NYSE:INSP - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $271.29.

A number of research firms recently commented on INSP. Stifel Nicolaus reiterated a "hold" rating and set a $210.00 price target on shares of Inspire Medical Systems in a report on Tuesday, January 2nd. Jefferies Financial Group started coverage on shares of Inspire Medical Systems in a report on Friday, January 19th. They issued a "buy" rating and a $245.00 price objective for the company. KeyCorp started coverage on Inspire Medical Systems in a report on Tuesday, February 6th. They set an "overweight" rating and a $278.00 target price on the stock. Mizuho reissued a "buy" rating and issued a $250.00 target price on shares of Inspire Medical Systems in a research report on Wednesday, March 27th. Finally, Morgan Stanley started coverage on Inspire Medical Systems in a research report on Tuesday, March 19th. They issued an "overweight" rating and a $250.00 target price for the company.

Inspire Medical Systems Stock Down 0.2 %

NYSE:INSP traded down $0.54 during mid-day trading on Friday, hitting $231.74. 305,032 shares of the stock traded hands, compared to its average volume of 462,760. The business's 50-day moving average price is $201.18 and its 200 day moving average price is $182.62. The company has a market cap of $7.02 billion, a PE ratio of -313.16 and a beta of 1.37. Inspire Medical Systems has a 12-month low of $123.27 and a 12-month high of $330.00.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 6th. The company reported $0.49 EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.53. The business had revenue of $192.51 million during the quarter, compared to analysts' expectations of $186.75 million. Inspire Medical Systems had a negative net margin of 3.39% and a negative return on equity of 3.93%. The business's quarterly revenue was up 39.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS. Analysts anticipate that Inspire Medical Systems will post -0.35 earnings per share for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other news, insider Randy Ban sold 12,230 shares of the business's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $185.37, for a total transaction of $2,267,075.10. Following the sale, the insider now directly owns 3,029 shares of the company's stock, valued at $561,485.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Inspire Medical Systems news, insider Randy Ban sold 12,230 shares of the company's stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $185.37, for a total value of $2,267,075.10. Following the sale, the insider now directly owns 3,029 shares of the company's stock, valued at $561,485.73. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Timothy P. Herbert sold 40,000 shares of the company's stock in a transaction on Monday, April 1st. The shares were sold at an average price of $205.09, for a total transaction of $8,203,600.00. Following the completion of the sale, the chief executive officer now directly owns 63,658 shares in the company, valued at $13,055,619.22. The disclosure for this sale can be found here. Over the last three months, insiders have sold 61,371 shares of company stock valued at $12,213,828. Corporate insiders own 4.10% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. US Bancorp DE raised its holdings in Inspire Medical Systems by 11.3% in the 1st quarter. US Bancorp DE now owns 2,284 shares of the company's stock valued at $586,000 after acquiring an additional 231 shares during the last quarter. HighTower Advisors LLC acquired a new stake in shares of Inspire Medical Systems during the 1st quarter worth approximately $452,000. Private Advisor Group LLC acquired a new stake in shares of Inspire Medical Systems during the 1st quarter worth approximately $203,000. PNC Financial Services Group Inc. increased its holdings in shares of Inspire Medical Systems by 668.6% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,422 shares of the company's stock worth $364,000 after buying an additional 1,237 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in shares of Inspire Medical Systems by 4.0% during the 1st quarter. Bank of Montreal Can now owns 14,694 shares of the company's stock worth $3,838,000 after buying an additional 563 shares during the last quarter. Institutional investors and hedge funds own 94.91% of the company's stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.